Biotech IPO news from FierceBiotech
NewsIn rocky market, Fluidigm withdraws IPO
Fluidigm was prepared to boldly go where few have gone this year: the public markets. The South San Francisco based company, which develops, manufactures and markets microfluidics products,... Read more...
Economic crisis rips biotech's bargaining position
Up to now it's been a sellers market for European biotechs when it comes to making deals with pharma organizations out to the beef up their pipelines. Now the Financial Times says that the credit... Read more...
Fluidigm attempts an IPO
Nanotech company Fluidigm is now going public. The South San Francisco based company plans to begin offering 5,300,000 shares at $14... Read more...
Venture groups switching to survival mode
The Washington Post examines a trend that may have a deep impact on biotechnology. With IPOs all but dead for now, venture... Read more...
Jazz Pharma axes staffers after delaying two trials
Jazz Pharmaceuticals says it needs to extend the development time line for two key drug programs, a move that triggered a decision to lay off 33 workers, or eight percent of its workforce. In a... Read more...
Peplin joins list of developers to drop IPO
You can count Peplin on the growing roster of developers that couldn't make a go of an IPO. The Emeryville, CA-based company cited "unfavorable market conditions" as its reason for dropping the IPO,... Read more...
Early IPO at Aldagen leaves analysts wondering
A pair of analysts has taken a cautious attitude toward Aldagen's plans for an $80 million IPO. The stem-cell company has no... Read more...
Codexis blueprints $100 million IPO
Codexis has decided to wade into frigid market waters with an IPO that may be used to raise upwards of $100 million. The company makes biocatalysts: enzymes or microbes that cause chemical... Read more...
Quark Pharma snares $27M for RNAi work
Quark Pharmaceuticals has garnered $27 million in a new round of venture financing. The RNAi developer attracted the support of SBI Asset Management and SBI Investment, subsidiaries of the... Read more...
Biotech going public with reverse mergers
With the IPO market waters looking distinctly chilly these days, if not outright frigid, BioWorld says that a growing number of biotech companies are turning to the reverse merger ploy to take... Read more...
| Press ReleasesPRESS RELEASE: Xanodyne Pharmaceuticals Files to Go Public Xanodyne Pharmaceuticals Files to Go Public NEWPORT, Ky. -- Xanodyne Pharmaceuticals, Inc. announced today that it has filed a registration statement with the U.S. Securities and Exchange Commission Read more >> PRESS RELEASE: Anacor files IPO ANACOR FILES REGISTRATION STATEMENT FOR INITIAL PUBLIC OFFERING Palo Alto, Calif. – August 31, 2007 – Anacor Pharmaceuticals announced today that it has filed a registration statement on Form Read more >> |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
